{"id":6345,"date":"2021-04-09T13:24:43","date_gmt":"2021-04-09T11:24:43","guid":{"rendered":"https:\/\/norinnova.nettrakett.net\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/"},"modified":"2024-04-18T13:17:11","modified_gmt":"2024-04-18T11:17:11","slug":"signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment","status":"publish","type":"post","link":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/","title":{"rendered":"Signed license agreement for new class of molecules for cancer treatment"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"6345\" class=\"elementor elementor-6345 elementor-2588\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6a50b485 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6a50b485\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;jet_parallax_layout_list&quot;:[{&quot;jet_parallax_layout_image&quot;:{&quot;url&quot;:&quot;&quot;,&quot;id&quot;:&quot;&quot;,&quot;size&quot;:&quot;&quot;},&quot;_id&quot;:&quot;5fabb9c&quot;,&quot;jet_parallax_layout_image_tablet&quot;:{&quot;url&quot;:&quot;&quot;,&quot;id&quot;:&quot;&quot;,&quot;size&quot;:&quot;&quot;},&quot;jet_parallax_layout_image_mobile&quot;:{&quot;url&quot;:&quot;&quot;,&quot;id&quot;:&quot;&quot;,&quot;size&quot;:&quot;&quot;},&quot;jet_parallax_layout_speed&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:50,&quot;sizes&quot;:[]},&quot;jet_parallax_layout_type&quot;:&quot;scroll&quot;,&quot;jet_parallax_layout_direction&quot;:&quot;1&quot;,&quot;jet_parallax_layout_fx_direction&quot;:null,&quot;jet_parallax_layout_z_index&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_x&quot;:50,&quot;jet_parallax_layout_bg_x_tablet&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_x_mobile&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_y&quot;:50,&quot;jet_parallax_layout_bg_y_tablet&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_y_mobile&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_size&quot;:&quot;auto&quot;,&quot;jet_parallax_layout_bg_size_tablet&quot;:&quot;&quot;,&quot;jet_parallax_layout_bg_size_mobile&quot;:&quot;&quot;,&quot;jet_parallax_layout_animation_prop&quot;:&quot;transform&quot;,&quot;jet_parallax_layout_on&quot;:[&quot;desktop&quot;,&quot;tablet&quot;]}]}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4f592183\" data-id=\"4f592183\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-53e34689 elementor-widget elementor-widget-text-editor\" data-id=\"53e34689\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<header>\n<div>\n<div>\n<h2><img fetchpriority=\"high\" decoding=\"async\" src=\"https:\/\/norinnova.no\/wp-content\/uploads\/2020\/12\/Lytix-foto-300x204.jpg\" alt=\"\" width=\"300\" height=\"204\"><\/h2>\n<p><\/p>\n<h3><b>Signed license agreement<\/b><\/h3>\n<p>A new class of peptides for cancer treatment developed at UiT-Norway&#8217;s Arctic University has now been licensed to the company Lytix Biopharma AS via Norinnova.&nbsp;<\/p>\n<p>The peptides were developed by inventors Johann Eksteen, John Sigurd Mj\u00f8en Svendsen and \u00d8ystein Rekdal.&nbsp;<\/p>\n<p>Participants from UiT-Norges Arktiske Universitet, Norinnova, Lytix, Norce, Oslo University Hospital and Gustave Roussy in Paris have participated in a verification project of the peptides partly funded by the Research Council of Norway and the Norwegian Cancer Society.<\/p>\n<p>The license agreement gives Lytix an exclusive right to further develop and commercialize this new class of molecules and helps build Lytix&#8217;s platform and pipeline of new candidates. One of the peptides has shown particularly promising results for cancer treatment in veterinary medicine, and Lytix has already initiated a strategic collaboration with the company Aurelius Therapeutics to ensure progress with this molecule.&nbsp; &nbsp;&nbsp;<\/p>\n<p>Nordlys has interviewed CEO of Lytix Biopharma \u00d8ystein Rekdal, read the story&nbsp;<a href=\"https:\/\/www.nord24.no\/nylig-tegnet-de-en-milliardavtale-na-har-tromso-firmaet-kjopt-rettighetene-til-kreftforskning-fra-uit\/s\/5-32-157509?fbclid=IwAR0OqMpNMexKOYhhbMQJP3MzayRosl1-omQpgEmQsiRSPoTusVvEqmvrUAo&amp;access=granted\">here<\/a>:&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/header>\n<div>\n<div>\n<div>\n<div>\n<div>&nbsp;<span style=\"font-family: 'Open Sans', sans-serif; font-size: 1rem; background-color: #feefe0; color: #292827;\">&nbsp;<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Signed license agreement A new class of peptides for cancer treatment developed at UiT-Norway&#8217;s Arctic University has now been licensed to the company Lytix Biopharma AS via Norinnova.&nbsp; The peptides were developed by inventors Johann Eksteen, John Sigurd Mj\u00f8en Svendsen and \u00d8ystein Rekdal.&nbsp; Participants from UiT-Norges Arktiske Universitet, Norinnova, Lytix, Norce, Oslo University Hospital and [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":5812,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[64],"tags":[],"class_list":["post-6345","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Signed license agreement for new class of molecules for cancer treatment &#8211; Norinnova %.<\/title>\n<meta name=\"description\" content=\"A new class of peptides for cancer treatment developed at UiT-Norway&#039;s Arctic University has now been licensed to the company Lytix Biopharma AS via Norinnova.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"STUD-ENT: Apply for 1 million kroner to develop your business idea\" \/>\n<meta property=\"og:description\" content=\"Student or recent master&#039;s degree candidate? Apply for up to NOK 1 million through the Research Council&#039;s STUD-ENT scheme. The funds will be used to further develop the business idea.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Norinnova\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/norinnova\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-09T11:24:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-18T11:17:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/norinnova.no\/wp-content\/uploads\/2019\/12\/5_StudENT2020_FB_Innlegg_1920x1080.jpg\" \/>\n<meta name=\"author\" content=\"Therese Lein\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Therese Lein\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/\"},\"author\":{\"name\":\"Therese Lein\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#\\\/schema\\\/person\\\/133ea7773480fccda51a363499e8003d\"},\"headline\":\"Signed license agreement for new class of molecules for cancer treatment\",\"datePublished\":\"2021-04-09T11:24:43+00:00\",\"dateModified\":\"2024-04-18T11:17:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/\"},\"wordCount\":179,\"publisher\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Lytix-foto-e1617966644593.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/\",\"url\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/\",\"name\":\"Signed license agreement for new class of molecules for cancer treatment &#8211; Norinnova %.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Lytix-foto-e1617966644593.jpg\",\"datePublished\":\"2021-04-09T11:24:43+00:00\",\"dateModified\":\"2024-04-18T11:17:11+00:00\",\"description\":\"A new class of peptides for cancer treatment developed at UiT-Norway's Arctic University has now been licensed to the company Lytix Biopharma AS via Norinnova.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Lytix-foto-e1617966644593.jpg\",\"contentUrl\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Lytix-foto-e1617966644593.jpg\",\"width\":1080,\"height\":734},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\\\/\\\/norinnova.no\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Signed license agreement for new class of molecules for cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/norinnova.no\\\/en\\\/\",\"name\":\"Norinnova Technology Transfer\",\"description\":\"Vi l\u00f8fter din id\u00e9 ut i verden\",\"publisher\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/norinnova.no\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#organization\",\"name\":\"Norinnova Technology Transfer AS\",\"url\":\"https:\\\/\\\/norinnova.no\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/norinnova_logo-1.png\",\"contentUrl\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/uploads\\\/2019\\\/02\\\/norinnova_logo-1.png\",\"width\":1512,\"height\":412,\"caption\":\"Norinnova Technology Transfer AS\"},\"image\":{\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/norinnova\\\/\",\"https:\\\/\\\/www.instagram.com\\\/norinnova_tech_transfer\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/norinnova-technology-transfer-as\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/en\\\/#\\\/schema\\\/person\\\/133ea7773480fccda51a363499e8003d\",\"name\":\"Therese Lein\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/wphb-cache\\\/gravatar\\\/453\\\/453e3b03a10dd2f487c47ce804dacd4cx96.jpg\",\"url\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/wphb-cache\\\/gravatar\\\/453\\\/453e3b03a10dd2f487c47ce804dacd4cx96.jpg\",\"contentUrl\":\"https:\\\/\\\/norinnova.no\\\/wp-content\\\/wphb-cache\\\/gravatar\\\/453\\\/453e3b03a10dd2f487c47ce804dacd4cx96.jpg\",\"caption\":\"Therese Lein\"},\"sameAs\":[\"https:\\\/\\\/norinnova.no\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Signed license agreement for new class of molecules for cancer treatment &#8211; Norinnova %.","description":"A new class of peptides for cancer treatment developed at UiT-Norway's Arctic University has now been licensed to the company Lytix Biopharma AS via Norinnova.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"STUD-ENT: Apply for 1 million kroner to develop your business idea","og_description":"Student or recent master's degree candidate? Apply for up to NOK 1 million through the Research Council's STUD-ENT scheme. The funds will be used to further develop the business idea.","og_url":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/","og_site_name":"Norinnova","article_publisher":"https:\/\/www.facebook.com\/norinnova\/","article_published_time":"2021-04-09T11:24:43+00:00","article_modified_time":"2024-04-18T11:17:11+00:00","og_image":[{"url":"https:\/\/norinnova.no\/wp-content\/uploads\/2019\/12\/5_StudENT2020_FB_Innlegg_1920x1080.jpg","type":"","width":"","height":""}],"author":"Therese Lein","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Therese Lein","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/"},"author":{"name":"Therese Lein","@id":"https:\/\/norinnova.no\/en\/#\/schema\/person\/133ea7773480fccda51a363499e8003d"},"headline":"Signed license agreement for new class of molecules for cancer treatment","datePublished":"2021-04-09T11:24:43+00:00","dateModified":"2024-04-18T11:17:11+00:00","mainEntityOfPage":{"@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/"},"wordCount":179,"publisher":{"@id":"https:\/\/norinnova.no\/en\/#organization"},"image":{"@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/norinnova.no\/wp-content\/uploads\/2020\/12\/Lytix-foto-e1617966644593.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/","url":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/","name":"Signed license agreement for new class of molecules for cancer treatment &#8211; Norinnova %.","isPartOf":{"@id":"https:\/\/norinnova.no\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/norinnova.no\/wp-content\/uploads\/2020\/12\/Lytix-foto-e1617966644593.jpg","datePublished":"2021-04-09T11:24:43+00:00","dateModified":"2024-04-18T11:17:11+00:00","description":"A new class of peptides for cancer treatment developed at UiT-Norway's Arctic University has now been licensed to the company Lytix Biopharma AS via Norinnova.","breadcrumb":{"@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#primaryimage","url":"https:\/\/norinnova.no\/wp-content\/uploads\/2020\/12\/Lytix-foto-e1617966644593.jpg","contentUrl":"https:\/\/norinnova.no\/wp-content\/uploads\/2020\/12\/Lytix-foto-e1617966644593.jpg","width":1080,"height":734},{"@type":"BreadcrumbList","@id":"https:\/\/norinnova.no\/en\/signed-license-agreement-for-new-class-of-molecules-for-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/norinnova.no\/en\/"},{"@type":"ListItem","position":2,"name":"Signed license agreement for new class of molecules for cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/norinnova.no\/en\/#website","url":"https:\/\/norinnova.no\/en\/","name":"Norinnova Technology Transfer","description":"Vi l\u00f8fter din id\u00e9 ut i verden","publisher":{"@id":"https:\/\/norinnova.no\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/norinnova.no\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/norinnova.no\/en\/#organization","name":"Norinnova Technology Transfer AS","url":"https:\/\/norinnova.no\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/norinnova.no\/en\/#\/schema\/logo\/image\/","url":"https:\/\/norinnova.no\/wp-content\/uploads\/2019\/02\/norinnova_logo-1.png","contentUrl":"https:\/\/norinnova.no\/wp-content\/uploads\/2019\/02\/norinnova_logo-1.png","width":1512,"height":412,"caption":"Norinnova Technology Transfer AS"},"image":{"@id":"https:\/\/norinnova.no\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/norinnova\/","https:\/\/www.instagram.com\/norinnova_tech_transfer\/","https:\/\/www.linkedin.com\/company\/norinnova-technology-transfer-as"]},{"@type":"Person","@id":"https:\/\/norinnova.no\/en\/#\/schema\/person\/133ea7773480fccda51a363499e8003d","name":"Therese Lein","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/norinnova.no\/wp-content\/wphb-cache\/gravatar\/453\/453e3b03a10dd2f487c47ce804dacd4cx96.jpg","url":"https:\/\/norinnova.no\/wp-content\/wphb-cache\/gravatar\/453\/453e3b03a10dd2f487c47ce804dacd4cx96.jpg","contentUrl":"https:\/\/norinnova.no\/wp-content\/wphb-cache\/gravatar\/453\/453e3b03a10dd2f487c47ce804dacd4cx96.jpg","caption":"Therese Lein"},"sameAs":["https:\/\/norinnova.no"]}]}},"_links":{"self":[{"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/posts\/6345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/comments?post=6345"}],"version-history":[{"count":0,"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/posts\/6345\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/media\/5812"}],"wp:attachment":[{"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/media?parent=6345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/categories?post=6345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/norinnova.no\/en\/wp-json\/wp\/v2\/tags?post=6345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}